Tpl2 induces castration resistant prostate cancer progression and metastasis-Reference-Cited by-同舟云学术

Tpl2 induces castration resistant prostate cancer progression and metastasis

Published:2014-10-10 Issue:9 Volume:136 Page:2065-2077
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Lee Hye Won¹²³,Cho Hyun Jung²,Lee Se Jeong²⁴,Song Hye Jin²⁴,Cho Hee Jin¹²,Park Min Chul⁵,Seol Ho Jun²,Lee Jung-Il²,Kim Sunghoon⁵,Lee Hyun Moo³,Choi Han Yong³,Nam Do-Hyun¹²,Joo Kyeung Min¹⁴

Affiliation:

1. Samsung Advanced Institute for Health Sciences and Technology (SAIHST); Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul South Korea

2. Department of Neurosurgery; Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul South Korea

3. Department of Urology; Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul South Korea

4. Department of Anatomy and Cell Biology; Sungkyunkwan University School of Medicine, Center for Molecular Medicine, Samsung Biomedical Research Institute; Suwon South Korea

5. Medicinal Bioconvergence Research Center, College of Pharmacy, Seoul National University; Seoul South Korea

Funder

Samsung Medical Center

the Ministry of Health & Welfare, Republic of Korea

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference49 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint;Birtle;Expert Rev Anticancer Ther,2013

3. Overcoming drug resistance and treating advanced prostate cancer;Semenas;Curr Drug Targets,2012